scispace - formally typeset
R

Richard N. Bergman

Researcher at Cedars-Sinai Medical Center

Publications -  489
Citations -  97005

Richard N. Bergman is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Insulin & Insulin resistance. The author has an hindex of 130, co-authored 477 publications receiving 91718 citations. Previous affiliations of Richard N. Bergman include University of Southern California & University of California, Los Angeles.

Papers
More filters
Journal ArticleDOI

Diets High in Protein or Saturated Fat Do Not Affect Insulin Sensitivity or Plasma Concentrations of Lipids and Lipoproteins in Overweight and Obese Adults

TL;DR: It is suggested that short-term intake of BCAAs can influence insulin dynamics, however, in this group of overweight and obese individuals, neither high protein nor SF intake affected insulin sensitivity or plasma concentrations of lipids and lipoproteins.
Journal ArticleDOI

Sequence data and association statistics from 12,940 type 2 diabetes cases and controls

Jason Flannick, +352 more
- 19 Dec 2017 - 
TL;DR: The GoT2D and T2D-GENES consortia catalogued variation from whole-genome sequencing and exome sequencing of 12,940 individuals of multiple ancestries as mentioned in this paper.
Journal ArticleDOI

The Measurement of Insulin Clearance.

TL;DR: This review focuses on methods used to calculate insulin clearance: from the early surrogate indices employing C-peptide:insulin molar ratio, to direct measurement methods used in animal models, to modeling-based techniques to estimate the components of insulin clearance.
Journal ArticleDOI

The multiphasic profile of free fatty acids during the intravenous glucose tolerance test is unresponsive to exogenous insulin.

TL;DR: Diurnal variation in FFA levels from 180 to 360 minutes in the IM-FSIGT and NS-Study suggests diurnal variation and not a dynamic related to insulin or the FSIGT protocol is responsible for the final suprabasal FFA plateau.
Journal ArticleDOI

Role of portal insulin delivery in the disappearance of intravenous glucose and assessment of insulin sensitivity.

TL;DR: It is concluded that portal insulin delivery per se does not significantly affect insulin's ability to normalize plasma glucose during acute glucose challenges.